Cargando…

Homogeneous BTK Occupancy Assay for Pharmacodynamic Assessment of Tirabrutinib (GS-4059/ONO-4059) Target Engagement

Bruton’s tyrosine kinase (BTK) is a clinically validated target for B-cell leukemias and lymphomas with FDA-approved small-molecule inhibitors ibrutinib and acalabrutinib. Tirabrutinib (GS-4059/ONO-4059, Gilead Sciences, Inc., Foster City, CA) is a second-generation, potent, selective, irreversible...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Helen, Truong, Hoa, Mitchell, Scott A., Liclican, Albert, Gosink, John J., Li, Wanying, Lin, Julie, Feng, Joy Y., Jürgensmeier, Juliane M., Billin, Andrew, Xu, Ren, Patterson, Scott, Pagratis, Nikos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6151956/
https://www.ncbi.nlm.nih.gov/pubmed/30011241
http://dx.doi.org/10.1177/2472555218786165